Cipralex, Entact e altri
Bibliografia - Quali fonti bibliografiche per Escitalopram?
- Abman S.H., Pediatr. Pulmonol. Suppl., 1999, 18, 201.
- Alexopoulos G.S. et al., 42nd Annual meeting of the American College of Neuropsychopharmacology, 2003.
- Alisky J.M., Singapore Medical J., 2006, 47, 1014.
- Alwan S. et al., NEJM, 2007, 356, 2684.
- Angermann C.E. et al., JAMA, 2016, 315 (24), 2683.
- Bergeron L. et al., Ann. Pharmacother., 2005, 39, 956.
- Bielski R.J. et al., 16th Congress of the European College of Neuropsychopharmacology, 2003.
- Burke W.J. et al., J. Clin. Psychiatry, 2002, 63, 331.
- Casper R.C. et al., J. Pediatr., 2003, 142, 402.
- Chambers C.D. et al., NEJM, 2006, 354, 579.
- Chris C., Australian Prescriber 2006, 29, 71.
- Clayton A. et al., J. Sex Med., 2007, 4 (4 Pt 1), 917.
- Colonna L. e al., 3rd Int. Forum on Mood and Anxiety Disorder, 2002.
- Colonna L. et al., Curr. Med. Res. Opin., 2005, 21 (10), 1659.
- Dalton S.O. et al., Arch. Intern. Med., 2003, 163, 59.
- Expertise Collective Inserm, Les édition Inserm: Paris; 2003.
- Food and Drug Administration – FDA, Lexapro – Label information, 2014
https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory (accesso: luglio 2016)
- Gorman J.M. et al., CNS Spectrum 2002, 7 (Suppl. 1), 40.
- Gulseren L. et al., Arch. Med. Res., 2005, 36 (2), 159.
- Gutierrez M.M. et al., Clin. Ther., 2003, 25 (4), 1200.
- Hayes B.D. et al., J. Emerg. Med., 2008.
- Jureidini J.N. et al., BMJ, 2004, 328, 879.
- Kirby D. et al., Internet J. Ger. Psychiatry, 2002, 17, 231.
- Kurdyak P.A. et al., J. Clin. Psychopharmacol., 2005, 25, 561.
- Lane RM. SSRI induced extrapyramidal side effects and akathisia: implication for treatment. J Psychopharmacol 1998; 12: 192-214.
- Laine K. et al., Arch. Gen. Psychiatry, 2003, 60, 720.
- Lancet, 2009, 373, 746.
- Layton D. et al., Eur. J. Clin. Pharmacol., 2001, 57, 167.
- Lepola U.M. et al., Int. Clin. psychopharmacol., 2003, 18 (4), 211.
Louik C. et al., NEJM, 2007, 356, 2675.
- Luìz-Lazaro PM, Cuevas Esteban J., European Neuropsychopharmacology 2007; 17 (suppl.4): 573.
- Malm H. et al., Obstet. Gynecol., 2005, 106, 1289.
- Mezuk B. et al., Osteoporos. 2007.
- Mills J.L., NEJM, 2006, 354, 636.
- Montgomery S.A. et al., Pharmacol. Toxicol., 2001, 88, 282.
- Montgomery S.A. et al., 44th Annual Meeting of the Scandinavian College of Neuropsychopharmacology, 2003.
- Moore N. et al., Int. Clin. Psychopharmacol., 2005, 20 (3), 131.
- Morag I. et al., J. Toxicol. Clin. 2004, 42, 97.
- Movig K.L. et al., Arch. Intern. Med., 2003, 163, 2354.
- Nulman I. et al., Am. J. Psychiatry, 2002, 159, 1889.
- Oberlander T.F. et al., Pediatr. Res., 2002, 51, 443.
- Orlova Y. et al., JAMA Neurol., 2018, doi: 10.1001/jamaneurol.2017.5144.
- Owens M.J. et al., Biol. Psychiatry, 2001, 50 (5), 345.
- Patron C. Ferrier I.N., BMJ, 2005, 334, 529.
- Rao N., Clin. Pharmacokinet., 2007, 46 (4), 281.
- Rapaport M.H. et al., J. Clin. Psychiatry, 2004, 65 (1), 44.
- Sanchez C. et al., Behav Pharmacol., 2003, 75, 903.
- Sansone R.A., Sansone L.A., Int. J. Psychiatry Med., 2003, 33 (1), 103.
- Serebruany V.L., Am. J. Med., 2006, 119, 113.
- Spigset O., Adielsson G., Int. Clin. Psychopharmacol., 1997, 12, 61.
- Stahl S.M. et al., J. Clin. Psychiatry, 2003, 64 (11), 1322.
- Steinacher L. et al., Eur. Neuropsychopharmacol., 2002, 12 (3), 255.
- von Moltke L.L. et al., Drug Metab. Dispos., 2001, 29, 1102.
- van Walraven C. et al., BMJ, 2001, 323, 655.
- Wade A. et al., Int. Clin. Psychopharmacol., 2002, 17 (3), 95.
- Wagner K.D. et al., JAMA, 2003, 290, 1033.
- Waugh J., Goa K.L., CNS Drugs, 2003, 17 (5), 343.
- Yasui-Furukori N. et al., Ther. Drug Monit., 2016, 38 (4), 483.
- Zeskind P.S., Stephens L.E., Pediatrics, 2004, 113, 368.
- Zeskind P.S. et al., Pediatr. Res., 2005, 57, 1624.